FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087087407> ?p ?o ?g. }

• W3087087407 endingPage "e001076" @default.
• W3087087407 startingPage "e001076" @default.
• W3087087407 abstract "Background Merkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with advanced MCC (aMCC) in clinical trials. To date, only results from clinical trials, patients treated in an expanded access program and very small numbers of patients have been reported. In this study, detailed real-world efficacy and toxicity data of avelumab in patients with aMCC are reported. Methods Patients with aMCC treated in four dedicated referral centers in the Netherlands were analyzed from February 2017 until December 2019. Patients were included if they had received at least one administration of avelumab, regardless of previous lines of therapy. Patient data were collected retrospectively from patient records. Primary endpoints were response rate (RR) and duration of response (DOR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Results Fifty-four patients received avelumab. Eight (15%) patients had locally advanced disease (laMCC). In 40 (74%) patients, avelumab was first-line treatment, these included all patients with laMCC. The median follow-up was 8.9 (range 0.5–35.9) months. RR was 57% (n=31) with 24% (n=13) of patients achieving a complete response. The median DOR was 8.4 (range 1.3–22.1) months and 23 (43%) patients had an ongoing response at the end of the study. The median PFS was 8.6 (95% CI 1.6–15.5) months, and the median OS was 25.8 (95% CI 9.1–42.4) months. Six (11%) patients experienced grade 3 toxicity. No grade 4–5 toxicity was seen. Conclusions In this real-world cohort, clinical efficacy and toxicity outcomes in clinical practice were in line with results from clinical trials and showed relatively high RRs and durable responses in patients with aMCC." @default.
• W3087087407 created "2020-09-25" @default.
• W3087087407 creator A5005729270 @default.
• W3087087407 creator A5005940004 @default.
• W3087087407 creator A5030905822 @default.
• W3087087407 creator A5059044768 @default.
• W3087087407 creator A5063932360 @default.
• W3087087407 creator A5068302495 @default.
• W3087087407 creator A5075441317 @default.
• W3087087407 creator A5077780102 @default.
• W3087087407 creator A5081011064 @default.
• W3087087407 date "2020-09-01" @default.
• W3087087407 modified "2023-10-18" @default.
• W3087087407 title "Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort" @default.
• W3087087407 cites W1909163072 @default.
• W3087087407 cites W1970096881 @default.
• W3087087407 cites W1983594071 @default.
• W3087087407 cites W2014202836 @default.
• W3087087407 cites W2018325776 @default.
• W3087087407 cites W2020547644 @default.
• W3087087407 cites W2053591120 @default.
• W3087087407 cites W2058393658 @default.
• W3087087407 cites W2066401368 @default.
• W3087087407 cites W2085487956 @default.
• W3087087407 cites W2132571078 @default.
• W3087087407 cites W2184261862 @default.
• W3087087407 cites W2283046649 @default.
• W3087087407 cites W2407443857 @default.
• W3087087407 cites W2498543837 @default.
• W3087087407 cites W2510686645 @default.
• W3087087407 cites W2514594482 @default.
• W3087087407 cites W2529149350 @default.
• W3087087407 cites W2563456874 @default.
• W3087087407 cites W2750984295 @default.
• W3087087407 cites W2772080242 @default.
• W3087087407 cites W2783234388 @default.
• W3087087407 cites W2783648588 @default.
• W3087087407 cites W2804564748 @default.
• W3087087407 cites W2890527521 @default.
• W3087087407 cites W2903317594 @default.
• W3087087407 cites W2912577878 @default.
• W3087087407 cites W2967623209 @default.
• W3087087407 cites W2969348491 @default.
• W3087087407 cites W2989716738 @default.
• W3087087407 cites W3015555708 @default.
• W3087087407 cites W3024881937 @default.
• W3087087407 cites W571385461 @default.
• W3087087407 doi "https://doi.org/10.1136/jitc-2020-001076" @default.
• W3087087407 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7511642" @default.
• W3087087407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32948651" @default.
• W3087087407 hasPublicationYear "2020" @default.
• W3087087407 type Work @default.
• W3087087407 sameAs 3087087407 @default.
• W3087087407 citedByCount "14" @default.
• W3087087407 countsByYear W30870874072021 @default.
• W3087087407 countsByYear W30870874072022 @default.
• W3087087407 countsByYear W30870874072023 @default.
• W3087087407 crossrefType "journal-article" @default.
• W3087087407 hasAuthorship W3087087407A5005729270 @default.
• W3087087407 hasAuthorship W3087087407A5005940004 @default.
• W3087087407 hasAuthorship W3087087407A5030905822 @default.
• W3087087407 hasAuthorship W3087087407A5059044768 @default.
• W3087087407 hasAuthorship W3087087407A5063932360 @default.
• W3087087407 hasAuthorship W3087087407A5068302495 @default.
• W3087087407 hasAuthorship W3087087407A5075441317 @default.
• W3087087407 hasAuthorship W3087087407A5077780102 @default.
• W3087087407 hasAuthorship W3087087407A5081011064 @default.
• W3087087407 hasBestOaLocation W30870874071 @default.
• W3087087407 hasConcept C121608353 @default.
• W3087087407 hasConcept C126322002 @default.
• W3087087407 hasConcept C141071460 @default.
• W3087087407 hasConcept C143998085 @default.
• W3087087407 hasConcept C203092338 @default.
• W3087087407 hasConcept C2777381376 @default.
• W3087087407 hasConcept C2777546739 @default.
• W3087087407 hasConcept C2777701055 @default.
• W3087087407 hasConcept C2778342957 @default.
• W3087087407 hasConcept C2780030458 @default.
• W3087087407 hasConcept C2780291066 @default.
• W3087087407 hasConcept C29730261 @default.
• W3087087407 hasConcept C535046627 @default.
• W3087087407 hasConcept C71924100 @default.
• W3087087407 hasConcept C72563966 @default.
• W3087087407 hasConceptScore W3087087407C121608353 @default.
• W3087087407 hasConceptScore W3087087407C126322002 @default.
• W3087087407 hasConceptScore W3087087407C141071460 @default.
• W3087087407 hasConceptScore W3087087407C143998085 @default.
• W3087087407 hasConceptScore W3087087407C203092338 @default.
• W3087087407 hasConceptScore W3087087407C2777381376 @default.
• W3087087407 hasConceptScore W3087087407C2777546739 @default.
• W3087087407 hasConceptScore W3087087407C2777701055 @default.
• W3087087407 hasConceptScore W3087087407C2778342957 @default.
• W3087087407 hasConceptScore W3087087407C2780030458 @default.
• W3087087407 hasConceptScore W3087087407C2780291066 @default.
• W3087087407 hasConceptScore W3087087407C29730261 @default.
• W3087087407 hasConceptScore W3087087407C535046627 @default.
• W3087087407 hasConceptScore W3087087407C71924100 @default.
• W3087087407 hasConceptScore W3087087407C72563966 @default.

• next